<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2024-23-3-26-39</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Artificial intelligence tools for molecular analysis of sensitization profiles in patients with atopic dermatitis and bronchial asthma</article-title><trans-title-group xml:lang="ru"><trans-title>Использование средств искусственного интеллекта для молекулярного анализа профилей сенсибилизации у больных атопическим дерматитом и бронхиальной астмой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5083-6637</contrib-id><name-alternatives><name xml:lang="en"><surname>Fomina</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Фомина</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Daria S. Fomina</p>
<p>3 Pekhotnaya St., Moscow 123182</p>
<p>Bld. 8, 2 Trubetskaya St., Moscow 119048</p>
<p>49a Beybitshilik St., Astana 010000, Kazakhstan</p></bio><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3</p>
<p>119048 Москва, ул. Трубецкая, 8, стр. 2</p>
<p>Республика Казахстан, 010000 Астана, ул. Бейбитшилик, 49 а</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9545-4720</contrib-id><name-alternatives><name xml:lang="en"><surname>Lebedkina</surname><given-names>M. S.</given-names></name><name xml:lang="ru"><surname>Лебедкина</surname><given-names>М. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Marina Sergeevna Lebedkina</p>
<p>3 Pekhotnaya St., Moscow 123182</p></bio><bio xml:lang="ru"><p>Марина Сергеевна Лебедкина</p>
<p>123182 Москва, ул. Пехотная, 3</p></bio><email>marina.ivanova0808@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0865-8355</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikitina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Никитина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ekaterina A. Nikitina</p>
<p>3 Pekhotnaya St., Moscow 123182</p>
<p>Bld. 8, 2 Trubetskaya St., Moscow 119048</p></bio><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3</p>
<p>119048 Москва, ул. Трубецкая, 8, стр. 2</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8013-5276</contrib-id><name-alternatives><name xml:lang="en"><surname>Dushkin</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Душкин</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexander D. Dushkin</p>
<p>3 Pekhotnaya St., Moscow 123182</p>
<p>27 Istra, Krasnogorsk city district, Moscow region 143515</p></bio><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3</p>
<p>143515 Московская обл., городской округ Красногорск, пос. Истра, 27</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6209-387X</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Чернов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Anton A. Chernov</p>
<p>3 Pekhotnaya St., Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0928-2054</contrib-id><name-alternatives><name xml:lang="en"><surname>Yukhnovskaya</surname><given-names>Yu. D.</given-names></name><name xml:lang="ru"><surname>Юхновская</surname><given-names>Ю. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Yulia D. Yukhnovskaya</p>
<p>Bld. 8, 2 Trubetskaya St., Moscow 119048</p></bio><bio xml:lang="ru"><p>119048 Москва, ул. Трубецкая, 8, стр. 2</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Evsegneeva</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Евсегнеева</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Irina V. Evsegneeva</p>
<p>Bld. 8, 2 Trubetskaya St., Moscow 119048</p></bio><bio xml:lang="ru"><p>119048 Москва, ул. Трубецкая, 8, стр. 2</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1930-5424</contrib-id><name-alternatives><name xml:lang="en"><surname>Karaulov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Караулов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexander V. Karaulov</p>
<p>Bld. 8, 2 Trubetskaya St., Moscow 119048</p></bio><bio xml:lang="ru"><p>119048 Москва, ул. Трубецкая, 8, стр. 2</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6010-7975</contrib-id><name-alternatives><name xml:lang="en"><surname>Lysenko</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Лысенко</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Mariana A. Lysenko</p>
<p>3 Pekhotnaya St., Moscow 123182</p>
<p>1A Ostrovityanova St., Moscow 117513</p></bio><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3</p>
<p>117513 Москва, ул. Островитянова, 1</p></bio><email>info@abvpress.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">City Clinical Hospital No. 52, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ г. Москвы «Городская клиническая больница № 52 Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Astana Medical University</institution></aff><aff><institution xml:lang="ru">НАО «Медицинский университет Астана»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Moscow City Oncology Hospital No. 62, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ г. Москвы «Московская городская онкологическая больница № 62 Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-10-07" publication-format="electronic"><day>07</day><month>10</month><year>2024</year></pub-date><volume>23</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>26</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2024-10-03"><day>03</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-10-03"><day>03</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; ,</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; ,</copyright-statement><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1470">https://bioterapevt.abvpress.ru/jour/article/view/1470</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> The variety of characteristics that should be taken into account in the clinical phenotyping of allergic diseases is currently being discussed. One of such characteristics is the individual spectrum of sensitization. An important stage in modern allergology has become the introduction of molecules / components for the detection of mediated reactions to specific class E immunoglobulins.</p> <p><bold>Aim.</bold> To determine the dominant phenotypes of sensitization in patients with severe atopic dermatitis and bronchial asthma based on the results of molecular diagnostics by the ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) method using machine learning.</p> <p><bold>Materials and methods</bold>. The study included 100 patients who were candidates for genetically engineered biological therapy (n = 63), severe atopic dermatitis (n = 20), or their combination (n = 17) were included. Allergodiagnosis was performed by the ImmunoCAP ISAC method.</p> <p><bold>Results</bold>. Based on the results of the study, 6 phenotypes were identified. In phenotype 1, pollen molecules (Amb a1, Phl p4) and crossed reactive food molecules (Mal d1, Ara h8, Gly m4, Act d8, Pru p3) are the leading, among epidermal molecules only Fel d1 (epidermal allergen) and Asp f6 (fungal allergen) are found. For phenotype 2, the significant allergens were fungal (Asp f6), epidermal (Can f1, Can f5, Can f6, Fel d1), food (Gad c1) and cross reactive food molecules (Mal d1, Pru p1. Ara h8, Cor a1.0401). In phenotype 4, only 3 allergen groups are present:</p> <p>epidermal (Fel d1, Fel d2, Can f5, Can f6, Can f3), fungal (Asp f6), and cross food allergy (Jug r3, Pru p3). Phenotype 5 and 6 are dominated by epidermal molecules (Can f1 and Fel d1), true food allergies allergens (Gad c1 and Gal d1 and Gad c1, Gal d1, Gal d3, respectively). In phenotype 3, a combination of the previously labeled molecules is noted.</p> <p><bold>Conclusion</bold>. Each of the identified phenotypes reveals a different set of molecules that can be used in real clinical practice to develop reduced panels, making them more accessible.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>В настоящее время обсуждается многообразие характеристик, которые должны учитываться при клиническом фенотипировании аллергических заболеваний. Одной из характеристик является спектр сенсибилизации. Важным этапом стало внедрение аллергокомпонентов для выявления опосредованной реакции к специфическим иммуноглобулинам класса E.</p> <p><bold>Цель исследования </bold>– определить доминирующие фенотипы сенсибилизации у пациентов с тяжелыми атопическим дерматитом и бронхиальной астмой на основе результатов молекулярной диагностики методом ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) с использованием машинного обучения.</p> <p><bold>Материалы и методы. </bold>В исследование включены 100 пациентов, являющихся кандидатами для проведения генно-инженерной биологической терапии по поводу тяжелых бронхиальной астмы (<italic>n</italic> = 63), атопического дерматита(<italic>n</italic>=20), сочетания заболеваний(<italic>n</italic>=17). Аллергодиагностику проводили методом ImmunoCAPISAC.</p> <p><bold>Результаты. </bold>По результатам исследования выделено 6фенотипов. В 1-м фенотипе лидирующее место занимают пыльцевые молекулы (Amba1,Phlp4) и перекрестные пищевые молекулы (Mald1,Arah8,Glym4,Actd8,Prup3), среди эпидермальных молекул встречается Fel d1, среди грибковых – Asp f6. Для 2-го фенотипа характерны грибковые (Asp f6), эпидермальные (Can f1, Can f5, Can f6, Fel d1), пищевые (Gad c1) и перекрестные пищевые молекулы (Mal d1, Prup1. Ara h8, Cor a1.0401). В 3-м фенотипе отмечается сочетание ранее обозначенных молекул. В 4-м фенотипе обнаружены 3 группы аллергенов: эпидермальные(Feld1,Feld2,Canf5,Canf6,Canf3), грибковые(Asp f6)и перекрестной пищевой аллергии (Jug r3, Pru p3). В 5-м и 6-м фенотипах преобладают эпидермальные молекулы (Can f1 и Fel d1), аллергены истинной пищевой аллергии (Gad c1 и Gal d1 и Gad c1, Gal d1, Gal d3 соответственно).</p> <p><bold>Заключение. </bold>Выявленные молекулы могут быть использованы в клинической практике с целью разработки усеченных панелей аллергочипов, что сделает их доступнее.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bronchial asthma</kwd><kwd>atopic dermatitis</kwd><kwd>component resolved diagnostic</kwd><kwd>ISAC ImmunoCAP</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бронхиальная астма</kwd><kwd>атопический дерматит</kwd><kwd>фенотипирование</kwd><kwd>молекулярная диагностика</kwd><kwd>ISAC ImmunoCAP</kwd><kwd>машинное обучение</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was supported by the Russian Science Foundation through the grant No. 23-75-30016 “AllergochipRUS”.</funding-statement><funding-statement xml:lang="ru">Исследование выполнено при поддержке гранта Российского научного фонда № 23-75-30016 «Аллергочип РФ».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Paller A.S., Spergel J.M., Mina-Osorio P., Irvine A.D. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol 2019;143(1):46–55. DOI: 10.1016/j.jaci.2018.11.006</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mersha T.B., Hershey K., Gurjit K. Precision medicine in allergic disorders. In: Middleton’s allergy: principles and practice. 9th ed., vol. 2. New York: Elsevier, 2020. Pp. 1441–1450.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Valenta R., Duchene M., Vrtala S. et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991;88(6):889–94. DOI:10.1016/0091-6749(91)90245-J</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>van Hage M., Hamsten C., Valenta R. ImmunoCAP assays: pros and cons in allergology. J Allergy Clin Immunol 2017;140(4):974–7. DOI: 10.1016/j.jaci.2017.05.008</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Vaňková R., Čelakovská J., Bukač J. et al. Sensitization to molecular components in 104 atopic dermatitis patients in relation to subgroups of patients suffering from bronchial asthma and allergic rhinitis. Acta Medica (Hradec Kralove) 2020;63(4):164–75. DOI: 10.14712/18059694.2020.59</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med 2023;11(7):589. DOI: 10.1016/S2213-2600(23)00230-8</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Atopicheskij dermatit. Proekt klinicheskih rekomendacij. 2020 g. RAAKI. URL: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf?ysclid=li7geerqe3115604531 .</mixed-citation><mixed-citation xml:lang="ru">Атопический дерматит. Проект клинических рекомендаций. 2020 г. РААКИ. URL: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf?ysclid=li7geerqe3115604531.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Ackermann M.R., Blömer J., Kuntze D., Sohler C. Analysis of agglomerative clustering. Algorithmica 2010;69(1):184–215. DOI:10.1007/s00453-012-9717-4</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ščevková J., Vašková Z., Sepšiová R. et al. Relationship between Poaceae pollen and Phl p 5 allergen concentrations and the impact of weather variables and air pollutants on their levels in the atmosphere. Heliyon 2020;6(7):e04421. DOI: 10.1016/j.heliyon.2020.e04421</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Čelakovská J., Bukač J., Cermákova E. et al. Analysis of results of specific IgE in 100 atopic dermatitis patients with the use of multiplex examination ALEX2-Allergy Explorer. Int J Mol Sci 2021;22(10):5286. DOI: 10.3390/IJMS22105286</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Scala E., Abeni D., Guerra E.C. et al. β-1,3-glucanase rOle e 9 and MnSOD rAsp f 6 IgE reactivity are the signature of atopic dermatitis in the Mediterranean area. Clin Exp Allergy 2020;50(4):487–98. DOI: 10.1111/cea.13555</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gaitanis G., Magiatis P., Hantschke M. et al. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012;25(1):106–41. DOI: 10.1128/CMR.00021-11</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ott H., Fölster-Holst R., Merk H.F. et al. Allergen microarrays: a novel tool for high-resolution IgE profiling in adults with atopic dermatitis. Eur J Dermatol 2010;20(1):54–61. DOI: 10.1684/ejd.2010.0810</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Aglas L., Soh W.T., Kraiem A. et al. Ligand binding of PR-10 proteins with a particular focus on the Bet v 1 allergen family. Curr Allergy Asthma Rep 2020;20(7):25. DOI: 10.1007/s11882-020-00918-4</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Biedermann T., Winther L., Till S.J. et al. Birch pollen allergy in Europe. Allergy 2019;74(7):1237–48. DOI: 10.1111/all.13758</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Iweala O.I., Choudhary S.K., Commins S.P. Food allergy. Curr Gastroenterol Rep 2018;20(5):17. DOI: 10.1007/s11894-018-0624-y</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Warren C.M., Jiang J., Gupta R.S. Epidemiology and burden of food allergy. Curr Allergy Asthma Rep 2020;20(2):6. DOI: 10.1007/s11882-020-0898-7</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Nilsson O.B., Binnmyr J., Zoltowska A. et al. Characterization of the dog lipocalin allergen Can f 6: the role in cross-reactivity with cat and horse. Allergy 2012;67(6):751–7. DOI: 10.1111/j.1398-9995.2012.02826.x</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Niespodziana K., Focke-Tejkl M., Linhart B. et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011;127(6):1562–70.e6. DOI:10.1016/j.jaci.2011.02.004</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Barradas Lopes J., Labrador-Horrilo M., Bartolomé B., Cunha L. The role of molecular allergens in the diagnosis of cat-pork syndrome: an unusual case report. Acta Med Port 2022;35(5):388–91. DOI: 10.20344/amp.15483</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Čelakovská J., Ettlerová K., Ettler K. et al. Sensitization to aeroallergens in atopic dermatitis patients: association with concomitant allergic diseases. J Eur Acad Dermatol Venereol 2015;29(8):1500–5. DOI: 10.1111/jdv.12891</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Nordlund B., Konradsen J.R., Kull I. et al. IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma. Allergy 2012;67(5):661–9. DOI: 10.1111/j.1398-9995.2012.02797.x</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Pónyai G., Hidvégi B., Németh I. et al. Contact and aeroallergens in adulthood atopic dermatitis. J Eur Acad Dermatol Venereol 2008;22(11):1346–55. DOI: 10.1111/j.1468-3083.2008.02886.x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Muthu V., Sehgal I.S., Dhooria S. et al. Utility of recombinant Aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis: a systematic review and diagnostic test accuracy meta-analysis. Clin Exp Allergy 2018;48(9):1107–36. DOI: 10.1111/cea.13216</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wojciechowska M., Żbikowska-Gotz M., Marek-Józefowicz L. et al. Allergic phenotypes in adult patients with atopic dermatitis, determined with the ISAC test (ImmunoCAP ISAC). Postepy Dermatol Alergol 2018;35(4):351–9. DOI: 10.5114/ada.2018.77664</mixed-citation></ref></ref-list></back></article>
